6 Meridian’s Myriad Genetics MYGN Stock Holding History

6 Meridian’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-21,314	Closed	-$580K	–	528
2019 Q4	$580K	Buy	21,314 +2,989	+16%	+$82.2K	0.05%	283
2019 Q3	$525K	Buy	+18,325	New	+$534K	0.05%	348
2018 Q3	–	Sell	-18,658	Closed	-$697K	–	489
2018 Q2	$697K	Sell	18,658 -294	-2%	-$9.93K	0.07%	158
2018 Q1	$560K	Sell	18,952 -4,411	-19%	-$149K	0.06%	175
2017 Q4	$802K	Buy	+23,363	New	+$788K	0.09%	123

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

6 Meridian's MYGN Position: Q1 2020 in Review

6 Meridian sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 21,314 shares — an estimated $580K sold.

6 Meridian first reported a position in MYGN in Q4 2017 and held it in 5 quarters. The position peaked at $802K in Q4 2017. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

6 Meridian reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
6 Meridian sold 21,314 Myriad Genetics shares in Q1 2020, an estimated $580K.
6 Meridian first reported a position in Myriad Genetics in Q4 2017 and held it in 5 quarters.
6 Meridian's Myriad Genetics position peaked at $802K in Q4 2017.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on 6 Meridian's 13F filing for Q1 2020, filed 14 Apr 2020.